A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies
← catalyst calendarSponsored by Century Therapeutics, Inc. (industry) · IPSC — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
28actual
Sites
16
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Strategic decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-24 | actual | When the study began enrolling |
| Primary completion | 2025-07-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-01 | actual | The whole study's end, after follow-up |
| First posted | 2022-04-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- R/R CD19-Positive B-Cell Malignancies
- Indolent Non-Hodgkin Lymphoma
- Aggressive Non-Hodgkin Lymphoma
Interventions
- Biological: CNTY-101
- Biological: IL-2
- Drug: Lymphodepleting Chemotherapy
Primary outcomes
what the primary-completion date above is the date OFMaximum Tolerated Dose (MTD) as Determined by the Percentage of Participants With Dose Limiting Toxicities (DLTs) and DLTs Based on Severity
measured Up to 28 days
Recommended Phase 2 Regimen (RP2R) as Recommended by the Safety Review Committee (SRC)
measured Up to 28 days
Permalink · IPSC's whole pipeline · Catalyst calendar · Every registered study · What changed